Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01812252 |
Recruitment Status :
Recruiting
First Posted : March 18, 2013
Last Update Posted : February 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Myelodysplastic Syndrome Secondary Myelodysplastic Syndrome | Drug: Azacitidine Drug: Decitabine Other: Quality-of-Life Assessment | Phase 2 |
PRIMARY OBJECTIVES:
I. To determine the effect of induction chemotherapy (IC) (intensive acute myeloid leukemia [AML]-like therapy), versus less intensive hypomethylating agents (HMA) as initial therapy, on failure-free survival.
SECONDARY OBJECTIVES:
I. Determine if IC (intensive AML-like therapy) in comparison to HMA as initial therapy, will affect transplantation frequency and quality of life.
II. Conduct exploratory analysis of post-HCT outcomes (overall survival, and relapse).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive decitabine or azacitidine intravenously (IV) or subcutaneously (SC) for 7 days. Treatment repeats every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive induction-like chemotherapy per standard of care or per experimental protocol. This study does not require a specific chemotherapy regimen for Arm B.
After completion of study treatment, patients are followed up for 18 months.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study) |
Actual Study Start Date : | April 2, 2013 |
Estimated Primary Completion Date : | October 1, 2023 |
Estimated Study Completion Date : | October 1, 2023 |

Arm | Intervention/treatment |
---|---|
Arm A (decitabine or azacitidine)
Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
|
Drug: Azacitidine
Given IV or SC
Other Names:
Drug: Decitabine Given IV or SC
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment |
Arm B (induction-like chemotherapy regimen)
Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
|
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment |
- Failure-free survival (failure defined as death or relapse) [ Time Frame: 18 months ]
- Changes in quality of life scores using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [ Time Frame: Baseline, pre-transplant, and up to 100 days post-transplant ]The quality-of-life questionnaires will be scored. Absolute scores will be reported. A distribution-based interpretation will be conducted using the standardized response mean to analyze changes in scores over time and differences between groups.
- Frequency at which the patients undergo transplantation [ Time Frame: Up to 18 months ]
- Overall Survival [ Time Frame: Up to 18 months ]
- Relapse [ Time Frame: Up to 18 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the 2008 World Health Organization classification system
- Patients must have measurable disease requiring cytoreduction, defined as a bone marrow myeloblast count >= 5% and < 20% on morphologic examination or by flow cytometry in cases in which adequate morphologic examination is not possible
- Patients must be considered to have an acceptable risk of early mortality with intensive chemotherapy as determined by the attending physician at the time of the initial visit; since the specific therapy within each arm will be determined after randomization, there is no threshold of organ dysfunction or performance status for inclusion
- Considered a potential transplant candidate; the attending/treating physician will determine transplant candidacy at the time of consent
- Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
Exclusion Criteria:
- A diagnosis of acute promyelocytic leukemia as defined by the 2008 World Health Organization classification system
- Previous treatment for MDS or AML with intensive chemotherapy regimen (induction chemotherapy) or hypomethylating agent
- Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
- Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- Females who are pregnant or breastfeeding
- Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
- Any uncontrolled or significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
- Clinical evidence suggestive of central nervous system (CNS) involvement with MDS unless a lumbar puncture confirms the absence of leukemic blasts in the cerebrospinal fluid (CSF)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01812252
Contact: Bart L. Scott | 206-667-1990 | bscott@fredhutch.org |
United States, Arizona | |
Mayo Clinic in Arizona | Completed |
Scottsdale, Arizona, United States, 85259 | |
United States, Ohio | |
Cleveland Clinic Foundation | Active, not recruiting |
Cleveland, Ohio, United States, 44195 | |
United States, Washington | |
Fred Hutch/University of Washington Cancer Consortium | Recruiting |
Seattle, Washington, United States, 98109 | |
Contact: Bart L. Scott 206-667-1990 bscott@fredhutch.org | |
Principal Investigator: Bart L. Scott | |
Kaiser Permanente Washington | Terminated |
Seattle, Washington, United States, 98112 |
Principal Investigator: | Bart L. Scott | Fred Hutch/University of Washington Cancer Consortium |
Responsible Party: | Fred Hutchinson Cancer Center |
ClinicalTrials.gov Identifier: | NCT01812252 |
Other Study ID Numbers: |
2661.00 NCI-2013-00538 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2661 2661.00 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) RG9215001 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) |
First Posted: | March 18, 2013 Key Record Dates |
Last Update Posted: | February 7, 2022 |
Last Verified: | February 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
myelodysplastic syndrome chronic myelomonocytic leukemia bone marrow transplant hypomethylating agent induction chemotherapy |
Preleukemia Leukemia, Myelomonocytic, Chronic Leukemia, Myelomonocytic, Juvenile Myelodysplastic Syndromes Syndrome Disease Pathologic Processes Leukemia Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases |
Hematologic Diseases Precancerous Conditions Leukemia, Myeloid Myelodysplastic-Myeloproliferative Diseases Azacitidine Decitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |